858 Stock Overview
Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, distributes, and sells pharmaceutical products in the People’s Republic of China and Hong Kong.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Extrawell Pharmaceutical Holdings Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$0.027 |
52 Week High | HK$0.065 |
52 Week Low | HK$0.026 |
Beta | 0.47 |
1 Month Change | -20.59% |
3 Month Change | -3.57% |
1 Year Change | -56.45% |
3 Year Change | -82.12% |
5 Year Change | -72.45% |
Change since IPO | -78.05% |
Recent News & Updates
Here's Why Extrawell Pharmaceutical Holdings (HKG:858) Can Afford Some Debt
Mar 18Extrawell Pharmaceutical Holdings (HKG:858) Is Making Moderate Use Of Debt
Dec 01Recent updates
Here's Why Extrawell Pharmaceutical Holdings (HKG:858) Can Afford Some Debt
Mar 18Extrawell Pharmaceutical Holdings (HKG:858) Is Making Moderate Use Of Debt
Dec 01We Think That There Are Some Issues For Extrawell Pharmaceutical Holdings (HKG:858) Beyond Its Promising Earnings
Aug 04Is Extrawell Pharmaceutical Holdings (HKG:858) Using Debt Sensibly?
Mar 15Some Shareholders May Object To A Pay Rise For Extrawell Pharmaceutical Holdings Limited's (HKG:858) CEO This Year
Aug 20Shareholder Returns
858 | HK Pharmaceuticals | HK Market | |
---|---|---|---|
7D | 0% | 6.0% | 3.5% |
1Y | -56.5% | -16.8% | -9.9% |
Return vs Industry: 858 underperformed the Hong Kong Pharmaceuticals industry which returned -17.6% over the past year.
Return vs Market: 858 underperformed the Hong Kong Market which returned -10.1% over the past year.
Price Volatility
858 volatility | |
---|---|
858 Average Weekly Movement | 17.8% |
Pharmaceuticals Industry Average Movement | 6.4% |
Market Average Movement | 7.4% |
10% most volatile stocks in HK Market | 14.7% |
10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 858's share price has been volatile over the past 3 months.
Volatility Over Time: 858's weekly volatility has increased from 12% to 18% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 169 | Yi Xie | www.extrawell.com.hk |
Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, distributes, and sells pharmaceutical products in the People’s Republic of China and Hong Kong. The company operates through Manufacturing, Trading, and Gene Development segments. It manufactures transfer factor oral solution, a dual immune regulator for the treatment of diseases caused by virus infection and weak cellular immune system; Wisk for the treatment of II-III degree of radio-injury of skin, normal common burn, actinic dermatitis, various infectious ulcers, and oral ulcers, as well as for trauma and post operation wound healing; and ZhouBang, a thromboxane synthetase inhibitor to prevent the coagulation of platelets and facilitate relaxation of blood vessels.
Extrawell Pharmaceutical Holdings Limited Fundamentals Summary
858 fundamental statistics | |
---|---|
Market cap | HK$64.53m |
Earnings (TTM) | -HK$154.28m |
Revenue (TTM) | HK$68.62m |
0.9x
P/S Ratio-0.4x
P/E RatioIs 858 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
858 income statement (TTM) | |
---|---|
Revenue | HK$68.62m |
Cost of Revenue | HK$36.12m |
Gross Profit | HK$32.50m |
Other Expenses | HK$186.78m |
Earnings | -HK$154.28m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.065 |
Gross Margin | 47.36% |
Net Profit Margin | -224.82% |
Debt/Equity Ratio | 10.3% |
How did 858 perform over the long term?
See historical performance and comparison